Discussions with leaders: Ken Herrmann, MD, MBA, and Michael Hofman, MBBS, FRACP, talk with Declan Murphy, FRACS, FRCS, about his career in genitourinary oncology and widely influential outreach activities in social media.. . . . . ***Page 1783***

FAPI PET/CT in nonmalignant diseases: Schmidkonz and colleagues offer a comprehensive review of fibroblast-activation protein inhibitor imaging in nonmalignant diseases to clarify current and potential roles of this class of molecules in nuclear medicine.. . . . . ***Page 1786***

FDA approval for theranostic agents: Perera and Morris present an educational overview of regulatory approval for novel radiopharmaceutical agents, including the importance of trial design for agents targeting prostate cancer and regulatory experience with ^{223}Ra and ^{177}Lu-PSMA-617. . . . ***Page 1793***

Nanoparticle diagnostics and theranostics: Pallares and colleagues provide an overview of nanoparticle-based imaging agents in the clinic and discuss preclinical progress and translational avenues for use in diagnostic and theranostic applications. . . . . ***Page 1802***

Histopathologic validation of ^{18}F-rhPSMA PET: Kroenke and colleagues investigate the accuracy and predictive value of 2 PSMA-targeting radiopharmaceuticals in assessment of lymph node metastases as validated by histopathology. . . . . ***Page 1809***

PSMA PET/CT for therapy assessment: Denis and colleagues use recent European recommendations to compare response assessment to a novel hormonal agent for metastatic castration-resistant prostate cancer between PSMA PET/CT and conventional imaging.. . . . . ***Page 1815***

Initial ^{68}Ga-PSMA-11 PET and outcomes: Moradi and colleagues examine the prognostic value of ^{68}Ga-PSMA-11 uptake in the primary lesion and presence of metastatic disease on PET in newly diagnosed prostate cancer before initial therapy. . . . . ***Page 1822***

^{68}Ga-RM2 PET in primary prostate cancer: Duan and colleagues compare preoperative ^{68}Ga-RM2 PET, targeting gastrin-releasing peptide receptors, with postsurgery histopathology in patients with newly diagnosed intermediate- or high-risk prostate cancer. . . . . ***Page 1829***

Setting up a theranostics center: Herrmann and members of a joint European Association of Nuclear Medicine, SNMMI, and International Atomic Energy Agency advisory group provide an enabling guide for radiopharmaceutical stakeholders interested in establishing dedicated theranostics centers. . . . . ***Page 1836***

Repetitive ^{68}Ga-FAPI PET acquisition: Glatting and colleagues report on the diagnostic value of repetitive early PET imaging with ^{68}Ga-FAPI-02, ^{68}Ga-FAPI-46, and ^{68}Ga-FAPI-74 for malignant, inflammatory/reactive, and degenerative lesions and describe implications for future ^{68}Ga-FAPI imaging. . . . . ***Page 1844***

FAP ligand with prolonged tumor uptake: Galbiati and colleagues detail the development and in vivo characterization of BiOncoFAP, a new dimeric fibroblast-activation protein–binding motif with extended tumor residence time and favorable tumor-to-organ ratios. . . . . ***Page 1852***

α-Particle and immunocytokine therapy: Minnix and colleagues investigate tumor reduction and survival outcomes with low-dose targeted α-therapy followed by a 4-dose immunocytokine regimen in mouse breast and colon cancer tumor models. . . . . ***Page 1859***

PET/CT for SiNET staging: Ouvrard and colleagues compare the respective values of ^{68}Ga-DOTATOC and ^{18}F-DOPA PET/CT for initial staging or presurgical work-up of patients with small-intestine neuroendocrine tumors.. . . . . ***Page 1865***

First-in-humans tissue factor PET: Loft and colleagues report on PET imaging with an ^{18}F-radiolabeled active-site inhibited version of the tissue factor natural ligand coagulation factor VII and describe its potential as a diagnostic companion for tissue-factor–targeted therapies. . . . . ***Page 1871***

HDL PET and esophageal cancer: Zheng and colleagues use a multimodal imaging approach to assess tumor uptake of exogenously administered, ^{89}Zr-labeled high-density lipoprotein nanoparticles in patients with esophageal cancer.. . . . ***Page 1880***

PET/CT and head and neck cancer staging: Subramaniam and colleagues look at multicenter interobserver agreement and accuracy in ^{18}F-FDG PET/CT imaging for staging of clinical N0 neck in head and neck cancer.. . . . . ***Page 1887***

^{166}Ho radioembolization in HCC: Reinders and colleagues establish the toxicity profile of ^{166}Ho radioembolization in patients with measurable, liver-dominant hepatocellular carcinoma and no or very limited curative treatment options.. . . . . ***Page 1891***

PET and GI graft-vs.-host disease: Cherk and colleagues explore the diagnostic utility of ^{18}F-FDG PET/CT in noninvasive assessment of patients with clinically suspected acute graft-versus-host disease of the gastrointestinal tract associated with allogeneic hemopoietic stem cell transplantation. . . . . ***Page 1899***

Cardiac amyloidosis in bone scan referrals: Nitsche and colleagues assess cardiac amyloidosis prevalence and outcomes in a large population referred for ^{99m}Tc-DPD bone scintigraphy over a decade-long period.. . . . . ***Page 1906***

PET imaging of GluN2B-NMDA: Ahmed and colleagues report on in vivo characterization of ^{18}F-OF-NB1 derivatives in nonhuman primates and comment on the potential for imaging of glutamate receptor subtype 2B–containing *N*-methyl-D-aspartate receptors in several neuropathologies.. . . . . ***Page 1912***

Evaluation of ^{18}F-PF-06445974: Wakabayashi and colleagues investigate the properties of the newly developed phosphodiesterase-4–selective radioligand ^{18}F-PF-06445974 in the brains of rodents, monkeys, and humans. . . . . ***Page 1919***

PET MIP prognostic biomarkers in DLBCL: Girum and colleagues explore whether total metabolic tumor volume and tumor dissemination can be replaced by artificial intelligence–generated surrogate features from maximum-intensity projections of whole-body ^{18}F-FDG PET in diffuse large B-cell lymphoma.. . . . . ***Page 1925***

Machine learning in sarcoidosis and lymphoma: Lovinfosse and colleagues describe development and validation of radiomics signatures to differentiate sarcoidosis from Hodgkin lymphoma and diffuse large B-cell lymphoma. . . . . ***Page 1933***

PET/CT multiorgan segmentation: Shiyam Sundar and colleagues introduce multiple-organ objective segmentation software that generates subject-specific, multiorgan segmentation using data-centric artificial intelligence principles to facilitate high-throughput systemic investigations via whole-body PET imaging. . . . . ***Page 1941***

Development of fluorinated NP-59: Brooks and colleagues prepare and evaluate an ^{18}F analog of the ^{131}I scintiscanning/SPECT agent NP-59 to serve as a PET agent for functional imaging of the adrenal glands based on cholesterol use. . . . . ***Page 1949***

^{68}Ga-FAPI PET for staging liver fibrosis: Pirasteh and colleagues research the utility of PET in staging liver fibrosis by correlating liver uptake of ^{68}Ga-labeled fibroblast-activation protein inhibitor with histology in a human-sized swine model. . . . . ***Page 1956***

Pediatric PET without sedation: Reichkendler and colleagues report on fast and flexible long-axial-field-of-view ^{18}F-FDG PET/CT acquisition in an unanesthetized 17-mo old with suspected incomplete Kawasaki disease.. . . . . ***Page 1962***